Tyrosine kinase inhibitors in renal cell carcinoma.
Potti
Anil
A
Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
George
Daniel J
DJ
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009367:Neoplasm Staging; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D025521:Tumor Suppressor Proteins / Q000235:genetics; D044767:Ubiquitin-Protein Ligases / Q000235:genetics; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D006623:von Hippel-Lindau Disease / Q000235:genetics
D004791:Enzyme Inhibitors; D025521:Tumor Suppressor Proteins; D044767:Ubiquitin-Protein Ligases; D051794:Von Hippel-Lindau Tumor Suppressor Protein; D020794:Receptor Protein-Tyrosine Kinases; C497446:VHL protein, human